Statins for Prevention of Cardiovascular Disease in Adults
Статины для профилактики сердечно-сосудистых заболеваний у взрослых
2016-11-13
SCID: 54.1/msg7fxxt
Discuss with AI
cardiovascular disease preventionmeta-analysisrandomized clinical trialsstatin therapysystematic review
Figures from the paper
Abstract (AI)
Importance: Cardiovascular disease (CVD), the leading cause of mortality and morbidity in the United States, may be potentially preventable with statin therapy. Objective: To systematically review benefits and harms of statins for prevention of CVD to inform the US Preventive Services Task Force. Data Sources: Ovid MEDLINE (from 1946), Cochrane Central Register of Controlled Trials (from 1991), and Cochrane Database of Systematic Reviews (from 2005) to June 2016. Study Selection: Randomized clinical trials of statins vs placebo, fixed-dose vs titrated statins, and higher- vs lower-intensity statins in adults without prior cardiovascular events. Data Extraction and Synthesis: One investigator abstracted data, a second checked data for accuracy, and 2 investigators independently assessed study quality using predefined criteria. Data were pooled using random-effects meta-analysis. Main Outcomes and Measures: All-cause mortality, CVD-related morbidity or mortality, and harms. Results: Nineteen trials (n = 71 344 participants [range, 95-17 802]; mean age, 51-66 years) compared statins vs placebo or no statin. Statin therapy was associated with decreased risk of all-cause mortality (risk ratio [RR], 0.86 [95% CI, 0.80 to 0.93]; I2 = 0%; absolute risk difference [ARD], -0.40% [95% CI, -0.64% to -0.17%]), cardiovascular mortality (RR, 0.69 [95% CI, 0.54 to 0.88]; I2 = 54%; ARD, -0.43% [95% CI, -0.75% to -0.11%]), stroke (RR, 0.71 [95% CI, 0.62 to 0.82]; I2 = 0; ARD, -0.38% [95% CI, -0.53% to -0.23%]), myocardial infarction (RR, 0.64 [95% CI, 0.57 to 0.71]; I2 = 0%; ARD, -0.81% [95% CI, -1.19 to -0.43%]), and composite cardiovascular outcomes (RR, 0.70 [95% CI, 0.63 to 0.78]; I2 = 36%; ARD, -1.39% [95% CI, -1.79 to -0.99%]). Relative benefits appeared consistent in demographic and clinical subgroups, including populations without marked hyperlipidemia (total cholesterol level <200 mg/dL); absolute benefits were higher in subgroups at higher baseline risk. Statins were not associated with increased risk of serious adverse events (RR, 0.99 [95% CI, 0.94 to 1.04]), myalgias (RR, 0.96 [95% CI, 0.79 to 1.16]), or liver-related harms (RR, 1.10 [95% CI, 0.90 to 1.35]). In pooled analysis, statins were not associated with increased risk of diabetes (RR, 1.05 [95% CI, 0.91 to 1.20]), although statistical heterogeneity was present (I2 = 52%), and 1 trial found high-intensity statins associated with increased risk (RR, 1.25 [95% CI, 1.05 to 1.49]). No trial directly compared titrated vs fixed-dose statins, and there were no clear differences based on statin intensity. Conclusions and Relevance: In adults at increased CVD risk but without prior CVD events, statin therapy was associated with reduced risk of all-cause and cardiovascular mortality and CVD events, with greater absolute benefits in patients at greater baseline risk.
Key Findings
1
A systematic review pooled 19 randomized trials involving 71,344 adults without prior cardiovascular events to assess statin benefits and harms.
2
Absolute benefits were greater among individuals with higher baseline cardiovascular risk.
3
Compared with placebo or no statin, statin therapy reduced all-cause mortality (RR 0.86; ARD −0.40%) and cardiovascular mortality (RR 0.69; ARD −0.43%).
4
Relative benefits were generally consistent across demographic and clinical subgroups, including adults without marked hyperlipidemia.
5
Statins reduced stroke (RR 0.71; ARD −0.38%), myocardial infarction (RR 0.64; ARD −0.81%), and composite cardiovascular outcomes (RR 0.70; ARD −1.39%).
Research Object
Adults without prior cardiovascular events receiving statin therapy
Research Subject
Benefits and harms of statins for primary prevention of cardiovascular disease, including effects on mortality and cardiovascular morbidity
Publication Details
Publication Date
2016-11-13
Journal
Publisher
ISSN
Access Type
Author Information
Download PDF
Subscribe to digest